IDH2 mutations are mutually exclusive with IDH1 mutations, and thus far, have been found rarely (3.3%) in WHO grade II or III gliomas (55) and much rarely (less than 1%) in GBMs (38). The gene discussed is IDH1; the disease is central nervous system cancer.